Furthermore, EGFR mutant tumors respond poorly to immune checkpoint inhibitors [36,37,38,39]; this is attributed to factors such as lower tumor mutation burdens in EGFR mutant lung cancer [40], but this remains poorly understood. The gene discussed is EGFR; the disease is lung cancer.